202 related articles for article (PubMed ID: 15158805)
21. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and pharmacological evaluation of new methyloxiranylmethoxyxanthone analogues.
Woo S; Kang DH; Nam JM; Lee CS; Ha EM; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2010 Sep; 45(9):4221-8. PubMed ID: 20619511
[TBL] [Abstract][Full Text] [Related]
23. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
24. Activities of novel nonglycosidic epipodophyllotoxins in etoposide-sensitive and -resistant variants of human KB cells, P-388 cells, and in vivo multidrug-resistant murine leukemia cells.
Anyanwutaku IO; Guo X; Chen HX; Ji Z; Lee KH; Cheng YC
Mol Pharmacol; 1996 Apr; 49(4):721-6. PubMed ID: 8609902
[TBL] [Abstract][Full Text] [Related]
25. 2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
Thapa P; Karki R; Thapa U; Jahng Y; Jung MJ; Nam JM; Na Y; Kwon Y; Lee ES
Bioorg Med Chem; 2010 Jan; 18(1):377-86. PubMed ID: 19939682
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes.
Kim MY; Duan W; Gleason-Guzman M; Hurley LH
J Med Chem; 2003 Feb; 46(4):571-83. PubMed ID: 12570378
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of the topoisomerase II-DNA cleavable complex by the ortho-quinone derivative of the antitumor drug etoposide (VP-16).
Gantchev TG; Hunting DJ
Biochem Biophys Res Commun; 1997 Aug; 237(1):24-7. PubMed ID: 9266822
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II.
Brel V; Annereau JP; Vispé S; Kruczynski A; Bailly C; Guilbaud N
Biochem Pharmacol; 2011 Dec; 82(12):1843-52. PubMed ID: 21924246
[TBL] [Abstract][Full Text] [Related]
29. Synthesis of new xanthone analogues and their biological activity test--cytotoxicity, topoisomerase II inhibition, and DNA cross-linking study.
Woo S; Jung J; Lee C; Kwon Y; Na Y
Bioorg Med Chem Lett; 2007 Mar; 17(5):1163-6. PubMed ID: 17194586
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and antitumor characterization of pyrazolic analogues of the marine pyrroloquinoline alkaloids: wakayin and tsitsikammamines.
Legentil L; Benel L; Bertrand V; Lesur B; Delfourne E
J Med Chem; 2006 May; 49(10):2979-88. PubMed ID: 16686539
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and topoisomerase II inhibitory and cytotoxic activity of oxiranylmethoxy- and thiiranylmethoxy-chalcone derivatives.
Na Y; Nam JM
Bioorg Med Chem Lett; 2011 Jan; 21(1):211-4. PubMed ID: 21115246
[TBL] [Abstract][Full Text] [Related]
32. A new class of naphthalimide-based antitumor agents that inhibit topoisomerase II and induce lysosomal membrane permeabilization and apoptosis.
Chen Z; Liang X; Zhang H; Xie H; Liu J; Xu Y; Zhu W; Wang Y; Wang X; Tan S; Kuang D; Qian X
J Med Chem; 2010 Mar; 53(6):2589-600. PubMed ID: 20170164
[TBL] [Abstract][Full Text] [Related]
33. DNA binding ellipticine analogues: synthesis, biological evaluation, and structure-activity relationships.
Ferlin MG; Marzano C; Gandin V; Dall'Acqua S; Dalla Via L
ChemMedChem; 2009 Mar; 4(3):363-77. PubMed ID: 19197924
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and antitumor activity of novel benzimidazole-5-carboxylic acid derivatives and their transition metal complexes as topoisomerease II inhibitors.
Galal SA; Hegab KH; Hashem AM; Youssef NS
Eur J Med Chem; 2010 Dec; 45(12):5685-91. PubMed ID: 20884089
[TBL] [Abstract][Full Text] [Related]
35. Structure-activity studies with cytotoxic anthrapyrazoles.
Begleiter A; Lin D; Larson KK; Lang J; Wu X; Cabral T; Taylor H; Guziec LJ; Kerr PD; Hasinoff BB; Guziec FS
Oncol Rep; 2006 Jun; 15(6):1575-80. PubMed ID: 16685398
[TBL] [Abstract][Full Text] [Related]
36. Establishment and characterization of a mouse FM3A cell mutant resistant to topoisomerase II-inhibitor NC-190.
Samata K; Yamagishi T; Ichihara T; Nanaumi K; Ikeda T; Ikeya H; Kuraishi A; Nakaike S; Kashiwagi K; Igarashi K
Cancer Chemother Pharmacol; 2002 Nov; 50(5):367-72. PubMed ID: 12439594
[TBL] [Abstract][Full Text] [Related]
37. Thanatop: a novel 5-nitrofuran that is a highly active, cell-permeable inhibitor of topoisomerase II.
Polycarpou-Schwarz M; Müller K; Denger S; Riddell A; Lewis J; Gannon F; Reid G
Cancer Res; 2007 May; 67(9):4451-8. PubMed ID: 17483360
[TBL] [Abstract][Full Text] [Related]
38. Topoisomerase II poisoning and antineoplastic action by DNA-nonbinding diacetyl and dicarboxaldoxime derivatives of ferrocene.
Vashisht Gopal YN; Jayaraju D; Kondapi AK
Arch Biochem Biophys; 2000 Apr; 376(1):229-35. PubMed ID: 10729210
[TBL] [Abstract][Full Text] [Related]
39. Design of new topoisomerase II inhibitors based upon a quinobenzoxazine self-assembly model.
Zeng Q; Kwok Y; Kerwin SM; Mangold G; Hurley LH
J Med Chem; 1998 Oct; 41(22):4273-8. PubMed ID: 9784102
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, biological evaluation, and molecular docking study of 3-(3'-heteroatom substituted-2'-hydroxy-1'-propyloxy) xanthone analogues as novel topoisomerase IIα catalytic inhibitor.
Jun KY; Lee EY; Jung MJ; Lee OH; Lee ES; Park Choo HY; Na Y; Kwon Y
Eur J Med Chem; 2011 Jun; 46(6):1964-71. PubMed ID: 21419530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
